BofA analyst Allen Lutz raised the firm’s price target on Cencora (COR) to $345 from $315 and keeps a Neutral rating on the shares. The firm is increasing its target multiples for McKesson (MCK) and Cencora following peer Cardinal Health’s (CAH) strong quarter highlighting the robust demand environment and positive broad-based industry utilization trends, the analyst tells investors. Cencora will report fiscal Q4 earnings before market open on November 5, the analyst noted.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on COR:
- COR Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Cencora price target raised to $340 from $334 at Mizuho
- Cencora price target raised to $380 from $350 at UBS
- Trump Trade: Trump administration prepares new probe into pharma prices
- Trump admin prepares new probe into U.S. pharma prices, FT says